



sartorius


# Research Xchange Forum 2018

Insights | Translation | Solutions

Trends and Challenges in Regenerative Medicine & Cell Therapy



March 20 – 21, 2018  
Sartorius Goettingen,  
Germany



The Sartorius & Science  
Prize for Regenerative  
Medicine & Cell Therapy

turning science **into solutions**



# What to expect

---

Learn about the latest Insights in regenerative medicine and cell therapy and exchange ideas as to their Translation into viable Solutions.

Our Research Xchange Forum brings together academic and industry experts to foster exchange and to stimulate dialog about the next generation of interdisciplinary research. Establish new contacts and explore the potential for collaborations with like-minded companies and academic professionals to gain a better understanding of their processes, workflows and challenges.


Deepen your discussions during a joint gala dinner and be there when the winner and the 3 finalists of "The Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy" receive their awards.  
Winner: U.S. \$25,000 + publication in *Science* print and online;  
3 finalists: U.S. \$5,000 per winner + publication in *Science* online.

We look forward to seeing you at our Research Xchange Forum.

# Highlights

---

- Keynote lectures by the winner and lectures by the 3 finalists of "The Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy", including a speech by *Science* editor Dr. Priscilla N. Kelly
- Keynote lectures on cellular immunotherapy by industry experts
- Inspirational speech by the Nobel Prize laureate of 2014 in chemistry Prof. Dr. Stefan W. Hell
- Panel discussion with stakeholders from industry and academia including *Science* editor Dr. Priscilla N. Kelly
- Gala dinner and award ceremony for the exceptional scientists receiving "The Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy"
- Thought-provoking dialog and networking opportunities with academic and industry experts
- Exclusive inside view into the work processes of Sartorius during an optional plant tour



The Sartorius & *Science*  
Prize for Regenerative  
Medicine & Cell Therapy

---

Awarded by



sartorius

Science



# Speaker line-up\*

## Top Academics

Keynote lecture by the winner and lectures by the 3 finalists of "The Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy"

## Guest Contributors



**Dr. Priscilla N. Kelly,**  
Washington DC, USA

AAAS/*Science*  
Editor

**Topic:** "How to publish in *Science*"



**Prof. Dr. Stefan W. Hell,**  
Goettingen, Germany

Max Planck Institute for Biophysical  
Chemistry

Managing Director and Nobel Prize laureate  
of 2014 in chemistry

Inspirational speech

© Peter Badge/  
Typos1 in cop. with  
Foundation Lindau  
Nobel Laureate  
Meetings – all  
rights reserved  
2017.

## Industry Experts



**Dr. Ulf Geumann,**  
Munich, Germany

apceth Biopharma GmbH  
Group Leader Preclinical Development

**Topic:** Mesenchymal stem cells in immunotherapy

**Overview:** apceth is harnessing the potential of mesenchymal stem cells (MSC), in which the mechanism of therapeutic effects are very different from that of CAR-T cells. The aim is to provide innovative cell-based gene therapies for the treatment of major indications such as cancer, chronic lung and kidney diseases and for immunomodulation.

apceth has created its allogenic therapeutic platform based entirely on the genetic engineering of MSC isolated from healthy donors.



**Francesca Bellintani,**  
Milan, Italy

MolMed  
Vector Downstream Process  
Development Manager

**Topic:** Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps

**Overview:** MolMed has implemented a large-scale process to meet the increasing demand for clinical and commercial grade vector production. There is a special focus on identification of challenges in the downstream | purification strategy to ensure efficient contaminant removal and preservation of viral infectivity.

# Speaker line-up\*



**Dr. Thierry Wurch**  
Suresnes, France

Servier  
Director of External Studies in  
Immuno-oncology

**Topic:** Allogenic approach developed by Servier and the preclinical data of UCART19

**Overview:** Servier is applying the Collectis' TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, "off-the-shelf" T cell based medicinal product.

UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies. It is currently being evaluated in a phase 1 clinical trials in relapsed | refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead).



**Dr. Nina G. Bauer**  
Basel, Switzerland

Lonza  
Assoc. Director of Commercial  
Development, Autologous Cell Therapies

**Topic:** Manufacturing strategies for patient scale cell therapies

**Overview:** The "Future Technologies" business area under the Pharma & Biotech division of Lonza has a focus on personalized medicine & cell therapy. One of the major challenges in these fields is the production of the patient-specific and patient-scale CAR-T cells or stem cells for treatment.

Lonza has partnered with Octane on the Octane Cocoon™ platform, which offers a ground-breaking innovation to address this challenge. Unlike current, labor-intensive production methods, this platform has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up.

# Registration

March 20 – 21, 2018

To register and to obtain further information, please visit our website:  
**[promotions.sartorius.com/rxf2018](http://promotions.sartorius.com/rxf2018)**

The registration fee includes admission, gala dinner, all coffee breaks, lunches and the optional plant tour. Advance registration is required.

**We offer an early bird discount until January 15, 2018**

	Industry   Business	Academia	PhD Students   Students
<b>Early Bird</b>	395 EUR	295 EUR	105 EUR
<b>Regular</b>	595 EUR	495 EUR	195 EUR
<b>Group Ticket</b>	Pay the 1st ticket and get 50% off for every additional registration		

## Venue:

Sartorius College  
Otto Brenner Strasse 20  
37079 Goettingen, Germany  
[www.sartorius.com](http://www.sartorius.com)

## Your Contact:

Romi Jeromis  
Sartorius Lab Instruments GmbH & Co. KG  
Phone: +49.551.308.2659  
[forum@Sartorius.com](mailto:forum@Sartorius.com)

If you have any questions,  
just contact us at any time – we would  
be happy to help you.

Please note that photos and videos will be  
taken during the event. If you do not wish  
to be photographed, please let us know  
upon registration.

**Follow us on Twitter #rxf2018**




# Research Xchange Forum 2018

Get insights into the latest developments from internationally renowned academic and industry speakers.

**Special Section:**

Lectures from "The Sartorius & *Science* Prize for Regenerative Medicine & Cell Therapy" Winner and Finalists.



The Sartorius & *Science*  
Prize for Regenerative  
Medicine & Cell Therapy

Awarded by



sartorius

Science

**March 20 – 21, 2018**  
**Register now!**

To register and to obtain further information, please visit our website:

[promotions.sartorius.com/rxf2018](https://promotions.sartorius.com/rxf2018)



Sartorius Lab Instruments  
GmbH & Co. KG  
Otto-Brenner-Strasse 20  
37079 Goettingen